Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Oncology

Advertisement

Advertisement

Featured

Samantha Shenoy
Videos
Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
05/10/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/10/2024
Oncology
Seth Wander, MD, PhD, Massachusetts General Hospital
Videos
Novel Endocrine Agents for Patients With HR-Positive Breast Cancer
05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Oladapo Yeku, MD, PhD, FACP
Conference Coverage
Incorporation of Immunotherapy in the Recurrent or Metastatic Setting for Patients With Cervical Cancer
05/08/2024

Featuring Oladapo Yeku, MD, PhD, FACP

Featuring Oladapo Yeku, MD, PhD, FACP...
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Oladapo Yeku, MD, PhD, FACP participated in a debate arguing for the incorporation of immunotherapy for patients with cervical cancer in the recurrent or metastatic setting.
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Oladapo Yeku, MD, PhD, FACP participated in a debate arguing for the incorporation of immunotherapy for patients with cervical cancer in the recurrent or metastatic setting.
At the 2024 Great Debates and...
05/08/2024
Oncology
Ying Liu, MD, MPH
The Case for Platinum-Based Chemotherapy for Patients With Platinum-Sensitive Recurrent Ovarian Cancer
05/08/2024

Featuring Ying Liu, MD, MPH

Featuring Ying Liu, MD, MPH
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.
At the 2024 Great Debates and...
05/08/2024
Oncology
Denise Yardley, MD, Sarah Cannon Research Institute
Videos
Is Age 50 Relevant for Decisions in Early HR-Positive Breast Cancer?
05/08/2024

Featuring Denise Yardley, MD

Featuring Denise Yardley, MD
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center
Videos
Sequential Antibody Drug Conjugates for Patients With Metastatic Breast Cancer
05/08/2024

Featuring Neil Iyengar, MD

Featuring Neil Iyengar, MD
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Bradley Monk, MD, FACOG
Conference Coverage
The Case for Early Use of Immunotherapy Plus Radiation/Chemo for Patients With High-Risk Cervical Cancer
05/08/2024

Featuring Bradley Monk, MD, FACOG

Featuring Bradley Monk, MD, FACOG ...
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Bradley Monk, MD, FACOG, argues for the first-line use of immune checkpoint inhibitors plus chemotherapy and radiation therapy for patients with cervical cancer.
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Bradley Monk, MD, FACOG, argues for the first-line use of immune checkpoint inhibitors plus chemotherapy and radiation therapy for patients with cervical cancer.
At the 2024 Great Debates and...
05/08/2024
Oncology
Bradley Monk, MD, FACOG
Conference Coverage
Use of PARP Inhibitors for Maintenance Therapy Among Patients With Advanced Epithelial Ovarian Cancer
05/08/2024

Featuring Bradley Monk, MD, FACOG

Featuring Bradley Monk, MD, FACOG ...
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Bradley Monk, MD, FACOG, discussed PARP inhibitors and determining the optimal maintenance therapy for women with advanced epithelial ovarian cancer. 
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Bradley Monk, MD, FACOG, discussed PARP inhibitors and determining the optimal maintenance therapy for women with advanced epithelial ovarian cancer. 
At the 2024 Great Debates and...
05/08/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Use of Liquid Biopsies to Reduce Time to Treatment for Patients With Lung Cancer
05/07/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.
At the Great Debates and Updates...
05/07/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Discussing the Need of Adjuvant Treatment After Neoadjuvant in Early Stage Lung Cancer
05/06/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
At the Great Debates and Updates...
05/06/2024
Oncology
Noa Biran, MD, John Theurer Cancer Center
Q&As
Step-Up Dosing for Multiple Myeloma Treatment in the Outpatient Setting
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the...
05/06/2024
Oncology

Advertisement

Advertisement

Advertisement

Insights From the ESMO Congress

Conference Coverage
Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma
11/22/2023

Stephanie Holland 

Stephanie Holland 
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Quiz
Tisotumab Vedotin for Cervical Cancer
11/21/2023
11/21/2023
Oncology
Juergen C. Becker, MD, PhD
Conference Coverage
Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma
11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD,...
11/20/2023
Oncology
Arlene Siefker-Radtke, MD, MD Anderson Cancer Center
Videos
Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma
11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD,...
11/16/2023
Oncology
Sara Lonardi, MD, Veneto Institute of Oncology
Videos
Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer
11/16/2023

Featuring Sara Lonardi, MD

Featuring Sara Lonardi, MD
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results...
11/16/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer
11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Oleg Gluz, MD
Conference Coverage
Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer
11/10/2023

Featuring Oleg Gluz, MD

Featuring Oleg Gluz, MD
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical...
11/10/2023
Oncology
News
Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy
11/10/2023
Allison Casey
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3...
11/10/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Allison Casey
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone...
11/10/2023
Oncology

Insights From the ASCO Annual Meeting

Stefan Knop, MD
Videos
Triplet vs Quadruplet Regimen for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
08/28/2023

Featuring Stefan Knop, MD

Featuring Stefan Knop, MD
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Stefan Knop, MD, presents...
08/28/2023
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
Mirvetuximab Soravtansine Improved Overall Survival for Patients With Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer
07/27/2023
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting,...
07/27/2023
Oncology
Reid Merryman, MD
Videos
Epcoritamab Plus Rituximab and Lenalidomide Regimen Demonstrates High Response Rates Among Patients With High-Risk Follicular Lymphoma
07/19/2023

Featuring Reid Merryman, MD

Featuring Reid Merryman, MD
At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.
At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.
At the 2023 ASCO meeting, Reid...
07/19/2023
Oncology
Conference Coverage
Sintilimab Added to Chemoradiotherapy Improved Event-Free Survival in High-Risk Nasopharyngeal Carcinoma
07/18/2023

Amber Denham

Amber Denham
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to...
07/18/2023
Oncology
Tsz Lun Yeung, MD
Videos
Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer
07/18/2023

Featuring Tsz Lun Yeung, MD

Featuring Tsz Lun Yeung, MD
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting,...
07/18/2023
Oncology
Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Videos
Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
07/17/2023

Featuring Paul Paik, MD

Featuring Paul Paik, MD
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer
07/17/2023

Featuring Ticiana Leal, MD 

Featuring Ticiana Leal, MD 
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Tycel Phillips, MD
Videos
Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL
06/26/2023

Featuring Tycel Phillips, MD

Featuring Tycel Phillips, MD
Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.
Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.
Tycel Phillips, MD, presented...
06/26/2023
Oncology
Carlotta Antoniotti, MD, PhD, University of Pisa
Videos
Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-Line Setting
06/22/2023

Featuring Carlotta Antoniotti, MD, PhD

Featuring Carlotta Antoniotti, MD, Ph...
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting,...
06/22/2023
Oncology
Kerry Rogers, MD
Videos
Ibrutinib Dose Adjustments in the Frontline Treatment of Patients With CLL
06/22/2023

Featuring Kerry Anne Rogers, MD

Featuring Kerry Anne Rogers, MD ...
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
At the 2023 ASCO Annual Meeting...
06/22/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Live Meetings

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma
05/10/2024

Stephanie Holland 

Stephanie Holland 
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective,...
05/10/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology
News
Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD
05/03/2024

Amber Denham

Amber Denham
According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...
According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...
According to a recent trial,...
05/03/2024
Oncology
News
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology
News
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement